The "John Lewicke and Michael Yakubovich Experimental Treatment Centers Act" establishes a framework for the creation of experimental treatment centers in New Hampshire, authorized by the Department of Health and Human Services. These centers will provide access to investigational drugs, biologics, or devices that have completed phase one of clinical trials but are not yet FDA-approved. The bill outlines eligibility criteria for patients, including a recommendation from their physician, informed consent, and a discussion of alternative treatments. It also defines key terms related to experimental treatments and emphasizes the goal of enhancing access to innovative healthcare while attracting clinical trials to the state.

The bill includes legal protections for physicians and treatment centers involved in experimental treatments, ensuring that the Board of Medicine cannot take action against a physician's license solely based on their recommendations. It establishes a licensing process for experimental treatment centers, which can operate without additional licensing if they meet specific standards. Each center must have a scientific review board to oversee treatment protocols, and they are allowed to create various payment arrangements with patients. Additionally, the bill mandates that centers allocate 2% of their net annual profits to support access to experimental treatments for qualifying residents. Notably, it amends RSA 151:2 to exempt these centers from needing a separate license, provided they comply with the new standards, and is set to take effect on January 1, 2027.

Statutes affected:
Introduced: 151:2
As Amended by the House: 151:2
HB1734 text: 151:2